Kriya Therapeutics
Kriya Therapeutics is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for ophthalmology, metabolic disease, and neurology, targeting prevalent chronic conditions like Geographic Atrophy, Type 1 Diabetes, MASH, and Trigeminal Neuralgia using its proprietary SIRVE computational vector design and STRIPE scalable GMP manufacturing platforms.
- Company typePrivate
- Founded2019
- HeadquartersPalo Alto, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kriya Therapeutics does
Kriya Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 that develops adeno-associated virus (AAV)-based gene therapies for patients with chronic, prevalent diseases across three therapeutic areas: ophthalmology (Geographic Atrophy, Thyroid Eye Disease), metabolic disease (Type 1 Diabetes, MASH), and neurology (Trigeminal Neuralgia, Focal Epilepsy). The company's lead assets include KRIYA-825 (Phase 1/2 for Geographic Atrophy), KRIYA-586 (Thyroid Eye Disease), KRIYA-839 (Type 1 Diabetes), KRIYA-497 (MASH via FGF21 expression), and KRIYA-748 (Trigeminal Neuralgia using a chemogenetically-gated ion channel). Kriya differentiates from earlier-generation gene therapy companies by targeting diseases affecting millions of patients rather than rare monogenic disorders, applying validated biological pathways with one-time AAV administration to deliver durable therapeutic protein expression.
Kriya operates a fully integrated platform consisting of two proprietary technology engines: SIRVE (System for Intelligent Rational Vector Engineering), a computationally-enabled platform for rational AAV vector design that uses generative deep learning, AlphaFold-based protein screening, and machine-learning-guided splicing elements to optimize expression, tissue specificity, manufacturability, and stability; and STRIPE (System to Realize Improved Production Efficiency), a scalable GMP manufacturing platform integrated with cell line technology and upstream/downstream process advances, located in a 51,350 sq ft facility in Research Triangle Park, NC with 50L, 500L, and 3,000L bioreactor capacity. The company augments these platforms with strategic in-licensing (e.g., the CR2-CR1 complement inhibitor from MUSC, Everads' suprachoroidal delivery technology) and acquisitions (Redpin Therapeutics for neurology in 2022; Tramontane Therapeutics for FGF21 metabolic assets in 2023). Key personnel include former leadership from Spark Therapeutics, AveXis, Sangamo, Pfizer, bluebird bio, and United Therapeutics, several of whom contributed to FDA-approved gene therapies (Luxturna, Kymriah, Beqvez, Zolgensma).
Kriya is pre-revenue. All pipeline programs are investigational and have not yet been approved; the company plans to commercialize gene therapy products upon regulatory approval, with distribution expected to flow through specialty pharmacies and hospital channels typical for biologics. The business model is therefore dependent on continued equity financing until first approval — the company has raised over $1.2 billion in venture capital across six rounds from Patient Square Capital (lead investor across Series B, C, and D), Premji Invest, Foresite Capital, QVT, Narya Capital, Dexcel Pharma, Bluebird Ventures, Woodline Partners, the T1D Fund, Peter Thiel, and others. Customer engagement currently runs through investigator-site clinical trials (Phase 1/2 underway for KRIYA-825, with additional programs planned to enter the clinic in 2025), medical conference presence (ASGCT, ARVO, ESOPRS), and peer-reviewed publications, with no commercial sales force, pricing, or distribution channel disclosed.
Kriya Therapeutics firmographics
Firmographics- Name
- Kriya Therapeutics
- Legal name
- Kriya Therapeutics, Inc.
- Website
- https://kriyatherapeutics.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Kriya Therapeutics is a clinical-stage biopharmaceutical company developing AAV-based gene therapies for ophthalmology, metabolic disease, and neurology, targeting prevalent chronic conditions like Geographic Atrophy, Type 1 Diabetes, MASH, and Trigeminal Neuralgia using its proprietary SIRVE computational vector design and STRIPE scalable GMP manufacturing platforms.
- Ownership category
- akta.pro rank
Kriya Therapeutics industry classification
Industry- Product category
- Gene Therapy Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Neurology/CNS Gene Therapies (HLAAACAH), Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)
Keywords
Where Kriya Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Kriya Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Others
Revenue model
- Gene Therapy Product Sales: Kriya is a clinical-stage biopharmaceutical company developing a pipeline of gene therapies. Upon regulatory approval, the company plans to commercialize its gene therapy products. All programs are investigational and not yet approved. No revenue has been generated to date.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Kriya Therapeutics product offering
Product offeringCore offering
Kriya Therapeutics is a clinical-stage biopharmaceutical company developing adeno-associated virus (AAV)-based gene therapies for prevalent chronic diseases in ophthalmology (Geographic Atrophy, Thyroid Eye Disease), metabolic disease (Type 1 Diabetes, MASH), and neurology (Trigeminal Neuralgia, Focal Epilepsy). The company operates a fully integrated platform that combines proprietary computational vector design (SIRVE) with scalable in-house GMP manufacturing (STRIPE) and AI-enabled analytics. All programs are investigational and not yet approved.
Product overview
Kriya Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of gene therapies across three therapeutic areas: ophthalmology (KRIYA-825 for Geographic Atrophy, KRIYA-586 for Thyroid Eye Disease), metabolic disease (KRIYA-839 for Diabetes, KRIYA-497 for MASH), and neurology (KRIYA-748 for Trigeminal Neuralgia, KRIYA-382 for Focal Epilepsy). The company operates on two proprietary technology platforms: SIRVE for computational vector engineering and STRIPE for scalable GMP manufacturing. Early pipeline programs include KT-A112, KT-A522, and KT-A832. The company has in-house manufacturing capabilities in Research Triangle Park, North Carolina with GMP production capacity at 50L, 500L, and 3,000L scale.
Differentiator
Problem solved
Functional benefit
Products and services
- KRIYA-825 AAV-based gene therapy expressing a complement CR2-CR1 fusion protein inhibitor for the treatment of Geographic Atrophy, designed for one-time suprachoroidal injection to inhibit complement C3 and C5 in the retina. Licensed from MUSC. For patients with Geographic Atrophy (approximately 2 million in US/EU).
- KRIYA-586 AAV gene therapy expressing an anti-IGF1R antibody for Thyroid Eye Disease, designed for one-time peribulbar injection with localized antibody expression in extraocular muscles and fat tissue. For patients with Thyroid Eye Disease (approximately 1 million in US/EU).
- KRIYA-839 AAV-based gene therapy providing insulin and glucokinase for diabetes treatment, delivered intramuscularly with the objective of driving durable glycemic control. For patients with Type 1 Diabetes (approximately 17 million insulin-using diabetics in US/EU).
- KRIYA-497
Quantifiable outcome
- KRIYA-825 demonstrated dose-dependent preservation of retinal thickness and suppression of C3b to iC3b protein levels in mouse model of sodium iodate-induced retinal degeneration
- +3 more outcomes
Companies that use Kriya Therapeutics
Customer profileNamed customers5 records
Segments1 record
Ideal customer profiles2 records
Kriya Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature4 records
Kriya Therapeutics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Everads TherapycoreKriya entered into an exclusive license, collaboration and supply agreement with Everads Therapy for the use of Everads' suprachoroidal delivery technology for Kriya's gene therapies for retinal diseases including Geographic Atrophy. Everads developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space. Kriya is using this for KRIYA-825 and other ophthalmology programs.
- Tramontane TherapeuticscoreKriya acquired Tramontane Therapeutics, a private gene therapy company focused on metabolic and neurodegenerative diseases including NASH. Tramontane is a spin out from Universitat Autònoma de Barcelona (UAB) and is now a wholly owned subsidiary of Kriya. The acquisition added portfolio of FGF21 assets including a lead AAV program expressing native FGF21 protein.
- Redpin TherapeuticscoreKriya acquired Redpin Therapeutics, adding a neurology pipeline to its gene therapy portfolio. Redpin focused on developing gene therapies for neurological conditions.
- Medical University of South Carolina (MUSC) Foundation for Research DevelopmentcoreKriya entered into an exclusive license agreement with the MUSC Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of Geographic Atrophy and other ocular diseases. This formed the basis for KRIYA-825 (AAV2.CR2-CR1).
- Universitat Autònoma de Barcelona (UAB)coreKriya established partnerships with leading academic and research institutions including UAB for FGF21 gene therapy research. UAB researchers (led by Prof. Fátima Bosch) generated preclinical data for KRIYA-497 published in Molecular Therapy, demonstrating fibrosis reversal in MASH models. Prof. Bosch serves on Kriya's Scientific Advisory Board.
- NIH (U.S. National Institutes of Health)minorKriya established partnerships with leading academic and research institutions, including the U.S. National Institutes of Health (NIH), as part of its platform infrastructure development.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Kriya Therapeutics competitors and assessment
Company assessmentDirect peers
- Regenxbio: Clinical-stage AAV gene therapy platform company with proprietary NAV vector technology and pipeline across ophthalmology, metabolic, and CNS indications. Highly comparable to Kriya as another platform-based AAV developer pursuing prevalent and rare disease gene therapies.
- Adverum Biotechnologies: Clinical-stage gene therapy company developing AAV-based therapies for ophthalmology, including wet AMD and diabetic macular edema. Direct competitor in ocular gene therapy space, especially relevant to Kriya's KRIYA-825 program in retinal disease.
- Lexeo Therapeutics: Clinical-stage gene therapy company with programs in cardiology and CNS, leveraging AAV and other delivery platforms. Comparable platform-based gene therapy developer with similar stage and capital base to Kriya.
- Tenaya Therapeutics: Clinical-stage gene therapy company focused on cardiac disease using AAV and other modalities. Comparable clinical-stage AAV developer with similar funding scale, headcount, and pipeline depth.
- Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other neuromuscular diseases. Comparable platform-based AAV developer at similar clinical and capital stage.
- MeiraGTx: Clinical-stage gene therapy company with integrated manufacturing capabilities and pipeline spanning ophthalmology, CNS, and salivary gland gene therapies. Direct platform peer to Kriya with shared focus on prevalent disease gene therapy and internal GMP manufacturing.
- uniQure: Clinical and commercial-stage gene therapy company with one approved AAV gene therapy (Hemgenix for hemophilia B). Closest direct peer given AAV platform, multiple clinical programs, and integrated manufacturing capabilities.
- bluebird bio: Gene therapy company with multiple approved products (Zynteglo, Lyfgenia, Skysona). Comparable gene therapy developer with approved AAV-based and lentiviral products, similar pioneering gene therapy profile to Kriya.
Emerging players
- Generation Bio: Clinical-stage genetic medicines company developing non-viral gene therapy using closed-ended DNA (ceDNA) platform. Emerging platform peer targeting similar chronic and rare diseases with a differentiated non-AAV delivery approach.
Broad incumbents
- Sangamo Therapeutics: Established genomic medicine company with multiple gene therapy and gene editing programs across rare disease. Broad incumbent in the gene therapy space; comparable to Kriya through partnership/alliance relationships (Roger Jeffs previously on Sangamo board; Sangamo alumni Zhu Pirot at Kriya).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Kriya Therapeutics social profiles
Digital presenceKriya Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kriya Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Kriya Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Kriya Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kriya Therapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kriya Therapeutics
What does Kriya Therapeutics do?
Kriya Therapeutics is a clinical-stage biopharmaceutical company developing adeno-associated virus (AAV)-based gene therapies for prevalent chronic diseases in ophthalmology (Geographic Atrophy, Thyroid Eye Disease), metabolic disease (Type 1 Diabetes, MASH), and neurology (Trigeminal Neuralgia, Focal Epilepsy). The company operates a fully integrated platform that combines proprietary computational vector design (SIRVE) with scalable in-house GMP manufacturing (STRIPE) and AI-enabled analytics. All programs are investigational and not yet approved.
Is Kriya Therapeutics a public or private company?
Kriya Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kriya Therapeutics founded?
Kriya Therapeutics was founded in 2019. It employs 101 to 250 people.
Where is Kriya Therapeutics based?
Kriya Therapeutics is headquartered in Palo Alto, United States, in the North America region.
How does Kriya Therapeutics make money?
One revenue line is on record: gene Therapy Product Sales.
Who are Kriya Therapeutics's main competitors?
Direct peers on record are Regenxbio, Adverum Biotechnologies, Lexeo Therapeutics, Tenaya Therapeutics, Solid Biosciences, MeiraGTx, uniQure and bluebird bio. Generation Bio is listed as an emerging player. Sangamo Therapeutics is listed as a broad incumbent.
Does Kriya Therapeutics have an API?
No public API is recorded for Kriya Therapeutics.
What industry is Kriya Therapeutics in?
Kriya Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 8731.